---
title: "美国食品药品监督管理局批准默克公司的Capvaxive疫苗用于成人肺炎球菌疾病"
description: "美国食品药品监督管理局批准默克公司的Capvaxive疫苗用于成人肺炎球菌疾病"

---


:::info

“智闻AI“ 是由人工智能编撰的刊物集合，确保您只获得最有价值的信息，旨在助您消除信息差，突破信息茧房的局限。  [了解更多 >>](/)

:::

# 美国食品药品监督管理局批准默克公司的Capvaxive疫苗用于成人肺炎球菌疾病

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">


美国食品药品监督管理局（FDA）批准了默克公司的Capvaxive疫苗，这是一种针对21种细菌株的肺炎球菌疫苗，专为成年人设计。该疫苗旨在预防严重的肺炎球菌疾病，包括每年导致约15万名美国成年人住院的肺炎。Capvaxive提供的保护范围比现有疫苗更广，可能覆盖65岁以上成年人中85%的侵袭性病例，相比之下，辉瑞的Prevnar 20疫苗覆盖率为51%。默克公司预计Capvaxive将迅速被采用，并将其定位为在面临其抗癌药物Keytruda专利即将到期的情况下，推动增长的关键因素。美国疾病控制与预防中心（CDC）的咨询小组将决定疫苗的适用人群，默克公司准备在夏末开始供应。
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 5    | Content provides balanced reporting on the vaccine's approval and its potential impact.    |
	| Social Impact | 4     | Content discusses a significant health issue, potentially influencing public health decisions.    |
	| Credibility    | 5    | Information is based on FDA approval, a credible source in medical regulation.    |
	| Potential    | 4    | The vaccine's approval could significantly impact public health by reducing pneumococcal disease cases.    |
	| Practicality    | 5    | The vaccine is ready for supply, directly applicable to healthcare settings.    |
	| Entertainment Value    | 2    | While informative, the content lacks typical entertainment elements.    |
</TabItem>
</Tabs>

[Full article>>](https://www.cnbc.com/2024/06/17/fda-approves-merck-pneumococcal-disease-vaccine-designed-for-adults.html)
